Literature DB >> 20187068

Induction chemotherapy in the management of head and neck cancer.

Matthew G Fury1, Jatin P Shah.   

Abstract

The strategy of induction chemotherapy prior to planned definitive local therapy for head and neck squamous cell carcinoma has been studied for over 30 years, and appears to have a role in select clinical situations. Here we review landmark studies regarding induction chemotherapy, both in the pre-taxane era and in the current taxane era, and we address some of the unresolved questions regarding the role of induction chemotherapy in head and neck cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20187068     DOI： 10.1002/jso.21438

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  4 in total

1.  Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy.

Authors:  Su Berrak; Sanjeev Chawla; Sungheon Kim; Harry Quon; Eric Sherman; Laurie A Loevner; Harish Poptani
Journal:  Acad Radiol       Date:  2011-08-10       Impact factor: 3.173

2.  Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma.

Authors:  Yuichiro Tada; Shin-Ichiro Maruya; Takashi Saotome; Kouki Miura; Tatsuo Masubuchi; Chihiro Fushimi; Isaku Okamoto; Etsuro Takeishi; Shuhei Yamada; Hiroaki Asai; Shin-Etsu Kamata
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

3.  A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.

Authors:  Matthew G Fury; Eric Sherman; Alan L Ho; Han Xiao; Frank Tsai; Oby Nwankwo; Camelia Sima; Adrian Heguy; Nora Katabi; Sofia Haque; David G Pfister
Journal:  Cancer       Date:  2013-02-13       Impact factor: 6.860

4.  Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

Authors:  M G Fury; E J Sherman; S S Rao; S Wolden; S Smith-Marrone; B Mueller; K K Ng; P R Dutta; D Y Gelblum; J L Lee; R Shen; S Kurz; N Katabi; S Haque; N Y Lee; D G Pfister
Journal:  Ann Oncol       Date:  2014-02-03       Impact factor: 32.976
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.